Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.450 EUR
−28.89 M EUR
28.57 M EUR
43.86 M
About GENFIT
Sector
CEO
Pascal Prigent
Headquarters
Loos
Website
Founded
1999
ISIN
FR0004163111
FIGI
BBG000QL0432
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange GENFIT S.A. EO -,25 stocks are traded under the ticker XUP.
We've gathered analysts' opinions on GENFIT S.A. EO -,25 future price: according to them, XUP price has a max estimate of 12.54 EUR and a min estimate of 7.00 EUR. Watch XUP chart and read a more detailed GENFIT S.A. EO -,25 stock forecast: see what analysts think of GENFIT S.A. EO -,25 and suggest that you do with its stocks.
Yes, you can track GENFIT S.A. EO -,25 financials in yearly and quarterly reports right on TradingView.
GENFIT S.A. EO -,25 is going to release the next earnings report on Apr 10, 2025. Keep track of upcoming events with our Earnings Calendar.
XUP earnings for the last half-year are 0.53 EUR per share, whereas the estimation was 0.31 EUR, resulting in a 70.97% surprise. The estimated earnings for the next half-year are 0.14 EUR per share. See more details about GENFIT S.A. EO -,25 earnings.
GENFIT S.A. EO -,25 revenue for the last half-year amounts to 61.20 M EUR, despite the estimated figure of 47.50 M EUR. In the next half-year revenue is expected to reach 37.55 M EUR.
XUP net income for the last half-year is 30.31 M EUR, while the previous report showed −8.04 M EUR of net income which accounts for 477.00% change. Track more GENFIT S.A. EO -,25 financial stats to get the full picture.
No, XUP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 25, 2025, the company has 159.00 employees. See our rating of the largest employees — is GENFIT S.A. EO -,25 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GENFIT S.A. EO -,25 EBITDA is 17.71 M EUR, and current EBITDA margin is −122.29%. See more stats in GENFIT S.A. EO -,25 financial statements.
Like other stocks, XUP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENFIT S.A. EO -,25 stock right from TradingView charts — choose your broker and connect to your account.